Real-World Outcomes of Using PD-1 Antibodies and BRAF + MEK Inhibitors for Adjuvant Melanoma Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the European Academy of Dermatology and Venereology: JEADV
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
J Eur Acad Dermatol Venereol 2022 Nov 25;[EPub Ahead of Print], K Schumann, C Mauch, KC Klespe, C Loquai, U Nikfarjam, M Schlaak, L Akçetin, P Kölblinger, M Hoellwerth, M Meissner, G Mengi, AD Braun, M Mengoni, R Dummer, J Mangana, MA Sindrilaru, D Radmann, C Hafner, J Freund, K Rappersberger, F Weihsengruber, F Meiss, L Reinhardt, F Meier, B Rainer, E Richtig, JM Ressler, C Höller, T Eigentler, T Amaral, WK Peitsch, U Hillen, W Harth, F Ziller, K Schatton, T Gambichler, L Susok, LV Maul, H Läubli, D Debus, C Weishaupt, S Börger, K Sievers, S Haferkamp, V Zenderowski, VA Nguyen, M Wanner, R Gutzmer, P Terheyden, K Kähler, S Emmert, A Thiem, M Sachse, S Gercken-Riedel, KM Kaune, KM Thoms, L Heinzerling, MV Heppt, S Tratzmiller, W Hoetzenecker, A Öllinger, A Steiner, T Peinhaupt, M Podda, S Schmid, U Wollina, T Biedermann, C PoschFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.